SynthesisBioMed research international2014
Prognostic significance of sentinel lymph node mapping in Merkel cell carcinoma: systematic review and meta-analysis of prognostic studies.
Synthesis in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- General health versus tumor stage: determinants of survival in Merkel cell carcinoma assessed by sentinel lymph node biopsy.Journal of cancer research and clinical oncology · 2026Article
- Sentinel Node Biopsy in Laryngeal Cancer: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Review
- Sentinel Lymph Node Biopsy: Is There a Role in Non-Melanoma Skin Cancer? A Systematic Review.Cancers · 2024Review
- Demographic and Clinicopathological Factors as Predictors of Lymph Node Metastasis in Merkel Cell Carcinoma: A Population-Based Analysis.Journal of clinical medicine · 2023Article
- Clinical Features and Prognosis of Merkel Cell Carcinoma in Elderly Patients.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- [Personalized medicine in the treatment of periocular tumors : Targeted treatment and use of immune checkpoint inhibitors].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2020Review
- Recent and Emerging Therapies for Cutaneous Squamous Cell Carcinomas of the Head and Neck.Current treatment options in oncology · 2020Review
- Histological pattern of Merkel cell carcinoma sentinel lymph node metastasis improves stratification of Stage III patients.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016Article
- Intra-Operative Lymphatic Mapping and Sentinel Node Biopsy in Laryngeal Carcinoma: Preliminary Results.Iranian journal of otorhinolaryngology · 2015Article
- Merkel cell carcinoma of the lower leg with retroperitoneal GIST: a very rare association.Wiener klinische Wochenschrift · 2015Article
- Sentinel lymph node biopsy for eyelid and conjunctival tumors: what is the evidence?International ophthalmology clinics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess through a systematic review and meta-analysis of the literature the prognostic implication of sentinel lymph node mapping in Merkel cell carcinoma (MCC). MATERIALS AND
methodsPubMed and SCOPUS databases were searched by using "Merkel AND sentinel" as keywords. All studies with prognostic information regarding SLN mapping in cN0 MCC patients were included. Hazard ratio (HR) for overall survival (OS) and disease free survival (DFS) was used as effect size.
resultsSLN biopsy predicted better DFS and OS as compared to the nodal observation in cN0 MCC patients (pooled HR for DFS: 1.61 (95% CI: 1.05-2.46), P = 0.028; pooled HR for OS: 1.08 (95% CI: 0.55-2.10), P = 0.8). Pathologically negative SLN (SLN-) patients had better OS (pooled HR: 4.42 (95% CI: 1.82-10.7), P = 0.0009) and DFS (pooled HR: 2.58 (95% CI: 1.78-3.73)) as compared to SLN+ patients.
conclusionSLN mapping can provide strong prognostic information regarding OS and DFS in cN0 MCC patients. More importantly, SLN mapping can improve DFS and possibly OS in cN0 MCC patients as compared to nodal observation. As MCC is a rare tumor, large multicenter prospective studies are still needed to validate the survival benefit of SLN mapping.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.